Bonbon 分子相互作用基礎模型展現湧現生物學能力
Emergent Biological Capabilities in a Foundation Model for Molecular Interactions
Bonbon 是一個僅以序列預訓練的生物學基礎模型,規模由 42M 擴至 1.6B 參數後呈現多項分子相互作用能力,並獲 NeurIPS 2026 主會議 Oral 接收,屬投稿前 0.4%。
Bonbon 在外部盲測中,跨 9 個疾病靶點達 61.5% 命中率,呈現序列模型如何連接分子作用判讀與候選分子篩選。
Bonbon is a vertical foundation model for biology that independently learned the hidden relationships governing molecular interactions, just as LLMs learned math without being explicitly trained on it. Accepted to the NeurIPS 2026 main track as an Oral (top 0.4% of submissions).
Trained on sequences alone, with no structure, physics, task-specific labels, or supervision, Bonbon developed emergent biological capabilities as we scaled it from 42M to 1.6B parameters. Pretraining loss fell smoothly, while new capabilities appeared sharply at the largest scale:
- What it does: predicts mechanism of action across six classes, including which molecules switch the same target on and which switch it off. Today this requires functional lab assays.
- Where it happens: localizes the binding site and distinguishes orthosteric from allosteric engagement on the same target.
- How it bonds: recognizes covalent binding and pinpoints the residue involved, without being told covalency is present.
- Which atoms matter: identifies the active moiety at single-bond resolution, work that usually takes many rounds of making and testing analogs.
All capabilities were evaluated zero-shot on held-out proteins and molecules.
The same representation space reaches state-of-the-art performance on widely used binding and affinity benchmarks, and runs at 2,500 molecular interactions per second on a single H100, about 50,000× faster than a leading co-folding model.
In blinded dose-response assays at an external CRO, de novo molecules ranked by Bonbon achieved a 61.5% hit rate across nine disease targets in seven protein families, compared with the ~0.1% typical of high-throughput screening. Every molecule was less than 60% similar to anything in training. Some examples:
- HDAC6: most known inhibitors rely on hydroxamate chemistry linked to toxicity. Bonbon found novel non-hydroxamate inhibitors.
- MNK2: novel inhibitors outside the documented chemical space for this cancer target.
- VEGFR2 and ELANE: both absent from training, yet Bonbon found confirmed inhibitors for each.
Why it matters
Most AI in drug discovery answers one narrow question: does a molecule fit a protein? But a molecule can fit perfectly and still do nothing, or the opposite of what you need. What it does, where it acts, how it holds, and which atoms drive it are usually answered through a long chain of separate assays and lab iterations.
Bonbon answers these questions together, in a single inference pass, at the scale biology demands. That collapses months of sequential experiments into one step, opens chemistry beyond known scaffolds, and puts the hardest drug programs within reach, including targets with no good starting points.
More broadly, it shows that the rules of molecular biology are learnable from sequence alone and emerge with scale. That is the foundation for moving from single interactions to pathways, cells, and understanding biology as a complex system.
來源:HuggingFace Daily Papers(社區熱門論文) · huggingface.co
